BioLineRx Ltd. (BLRX) is primed for evolution with the beta value of 2.10 – Invest Chronicle

BioLineRx Ltd. (BLRX) is primed for evolution with the beta value of 2.10

For the readers interested in the stock health of BioLineRx Ltd. (BLRX). It is currently valued at $2.85. When the transactions were called off in the previous session, Stock hit the highs of $2.6999, after setting-off with the price of $2.64. Company’s stock value dipped to $2.63 during the trading on the day. When the trading was stopped its value was $2.63.Recently in News on October 13, 2021, BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization. – Results demonstrate significant cost benefits of using Motixafortide in combination with G-CSF as standard-of-care mobilization therapy for all multiple myeloma patients undergoing autologous stem cell transplantation -. You can read further details here

BioLineRx Ltd. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $6.34 on 05/04/21, with the lowest value was $2.32 for the same time period, recorded on 01/27/21.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


BioLineRx Ltd. (BLRX) full year performance was 62.35%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BioLineRx Ltd. shares are logging -55.05% during the 52-week period from high price, and 103.57% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.40 and $6.34.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3106888 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the BioLineRx Ltd. (BLRX) recorded performance in the market was 4.37%, having the revenues showcasing -13.77% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 126.71M, as it employees total of 48 workers.

Analysts verdict on BioLineRx Ltd. (BLRX)

During the last month, 0 analysts gave the BioLineRx Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 2.90, with a change in the price was noted -0.22. In a similar fashion, BioLineRx Ltd. posted a movement of -7.10% for the period of last 100 days, recording 817,615 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BLRX is recording 0.08 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.04.

>> 7 Top Picks for the Post-Pandemic Economy << 

BioLineRx Ltd. (BLRX): Technical Analysis

Raw Stochastic average of BioLineRx Ltd. in the period of last 50 days is set at 46.15%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 62.85%. In the last 20 days, the company’s Stochastic %K was 31.74% and its Stochastic %D was recorded 23.32%.

Let’s take a glance in the erstwhile performances of BioLineRx Ltd., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 4.37%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -3.66%, alongside a boost of 62.35% for the period of the last 12 months. The shares increased approximately by -1.50% in the 7-day charts and went up by -8.04% in the period of the last 30 days. Common stock shares were lifted by -13.77% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam